Copolymer-Based Sarcolemma Stabilization for Protecting Dystrophic Skeletal Muscles in Vivo

基于共聚物的肌膜稳定保护体内营养不良的骨骼肌

• 批准号: 10403499
• 负责人: JOSEPH Mark METZGER
• 金额: $ 46.17万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10403499
• 关键词: Acute; Age; Cardiac; Chemical Engineering; Chemicals; Clinical Treatment; Clinical Trials; DNA Sequence Alteration; Data; Defect; Disease; Disease Outcome; Disease Progression; Dissection; Duchenne muscular dystrophy; Exons; Failure; Foundations; Genes; Genetic; Goals; Health; Immunosuppression; Investigation; Lesion; Life; Limb structure; Link; Membrane; Modeling; Molecular; Muscle; Muscular Atrophy; Muscular Dystrophies; Mutation; Myocardium; Nonsense Mutation; Oxidative Stress; Pathway interactions; Patients; Pharmacodynamics; Physiological; Progressive Disease; Respiratory Muscles; Sarcolemma; Skeletal Muscle; Striated Muscles; Structure; Teenagers; Testing; Therapeutic; Time; Treatment Efficacy; United States National Institutes of Health; Wheelchairs; base; boys; clinical application; copolymer; design; effective therapy; in vivo; insight; mitochondrial dysfunction; novel; novel strategies; novel therapeutics; preclinical study; preservation; protective effect; public health relevance; respiratory; skeletal muscle wasting

Abstract Duchenne muscular dystrophy (DMD) is a devastating and universally fatal X-linked recessive disease of progressive striated muscle deterioration. DMD boys have severe skeletal muscle wasting early in life and they are typically wheelchair bound by age 10-12. DMD is fatal by the late teens to mid-twenties due to cardiac muscle and respiratory muscle failure. These grim realities underscore the tremendous urgency to discover and implement new approaches and therapies that could impact disease progression and outcomes in DMD. Significance of this proposal to the NIH is tremendous. There is no cure for DMD, or any effective clinical treatment that can halt or reverse the disease. This application derives outstanding health significance and impact by focusing on first-in-class synthetic membrane stabilizers that directly target the primary physiological defect in DMD: severe muscle membrane instability. Membrane stabilizers confer marked protection to dystrophic cardiac muscle, however, until now, dystrophic skeletal muscles were not significantly protected, tempering enthusiasm in the DMD field for this class of therapy. Now, for the first time to our knowledge, we find that pharmacodynamically optimized membrane stabilizers have a dramatic protective effect in dystrophic limb skeletal muscles in vivo. This potential therapeutic breakthrough has great significance to the NIH as a new viable approach to treat dystrophic striated muscles. The overarching hypothesis directing this proposal is that mechanistically guided structure-function analysis of synthetic block copolymers will illuminate new fundamental insights into the cellular basis of how membrane stabilization protect muscles. These mechanistically guided studies have great potential impact as they serve the required foundation in seeking the ultimate goal of effective long-term protection to dystrophic striated muscles in vivo.

摘要 Duchenne肌营养不良症(DMD)是一种毁灭性的、普遍致命的X连锁隐性遗传病 进行性横纹肌退化。DMD男孩在生命早期就有严重的骨骼肌萎缩，他们 通常是10-12岁的轮椅。DMD在十几岁到二十五岁左右是致命的，原因是心肌 和呼吸肌衰竭。这些严峻的现实突显了发现和发现 实施新的方法和疗法，可能会影响DMD的疾病进展和结局。 这项建议对美国国立卫生研究院的意义是巨大的。没有治愈DMD的方法，也没有任何有效的临床治疗方法 可以阻止或逆转疾病的治疗。这款应用程序具有突出的健康意义和 专注于一流的合成膜稳定剂的影响，这些稳定剂直接针对主要生理 DMD的缺陷：严重的肌膜不稳定。膜稳定剂可显著保护 营养不良的心肌，然而，到目前为止，营养不良的骨骼肌没有得到明显的保护， 缓和了DMD领域对这门课的热情。现在，据我们所知，我们第一次发现 药效学优化的膜稳定剂对营养不良肢体有显著的保护作用 活体中的骨骼肌。这一潜在的治疗突破对NIH作为一种新的 治疗营养不良横纹肌的可行方法。指导这一提议的首要假设是 合成嵌段共聚物的力学导引结构-功能分析将揭示新的基本原理 对膜稳定如何保护肌肉的细胞学基础的见解。这些机械导引 研究具有巨大的潜在影响，因为它们为寻求有效的最终目标提供了必要的基础 对体内营养不良横纹肌的长期保护作用。